

Publication

ACE inhibitor use and risk of cataract: a case-control analysis

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID 4525420

Author(s) Becker, Claudia; Jick, Susan S.; Meier, Christoph R. **Author(s)** at **UniBasel** Meier, Christoph R.; Becker, Claudia;

Year 2019

Title ACE inhibitor use and risk of cataract: a case-control analysis

Journal The British journal of ophthalmology

Volume 103 Number 11

Pages / Article-Number 1561-1565

Keywords drugs; epidemiology

Mesh terms Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors, therapeutic use; Antihypertensive Agents, therapeutic use; Case-Control Studies; Cataract, diagnosis, epidemiology; Cataract Extraction, statistics & numerical data; Databases, Factual; Drug Prescriptions, statistics & numerical data; Female; Humans; Male; Middle Aged; Risk Factors; United Kingdom, epidemiology Use of ACE inhibitors (ACEIs) has been associated with an increased risk of cataract in a previous observational study in humans. In contrast, ACEIs were associated with beneficial effects on cataract development in experimental studies. We assessed the risk of cataract in relation to exposure to ACEI and other antihypertensive drugs.; This is a case-control study based on data from the UK-based Clinical Practice Research Datalink (CPRD). We included first-time cataract patients aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls. We matched the controls to cases on age, sex, general practice, date of first cataract (ie, index date) and years of history in the CPRD prior to the index date. We assessed the number of prescriptions for ACEI and other antihypertensive drugs in detail and explored the use of single ACEI substances. We performed conditional logistic regression and conducted various sensitivity analyses to test the robustness of our findings. We calculated the risk of cataract associated with previous exposure to ACEI, measured as OR with 95% CIs, and adjusted the multivariable model for body mass index, smoking, diabetes, hypertension, prescriptions of systemic corticosteroids and other antihypertensive drugs.; We identified 206 931 cataract cases and the same number of matched controls. Use of ACEI was not associated with a materially altered risk of cataract compared with non-use of ACEI, neither in the main analysis (OR 1.06, 95% CI 1.04 to 1.08) nor in any of the sensitivity or stratified analyses.; In our large observational study, use of ACEI was not associated with an altered risk of cataract.

ISSN/ISBN 1468-2079

edoc-URL https://edoc.unibas.ch/74307/

Full Text on edoc No;

Digital Object Identifier DOI 10.1136/bjophthalmol-2018-312980

PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/30733210

Document type (ISI) Journal Article